What is Bausch Health's gross profit margin?

What guidance did Bausch Health's management provide for the next earnings period?

What is the market's earnings forecast for Bausch Health next quarter?

What were the key takeaways from Bausch Health’s earnings call?

Did Bausch Health beat or miss consensus estimates last quarter?

What were the key takeaways from Bausch Health's earnings call?

What is the revenue and EPS growth rate for Bausch Health year over year?

What is Bausch Health's latest dividend and current dividend yield?

- **Record Growth**: 11 straight quarters of revenue and EBITDA growth, with Q4 2025 revenue up 9% YoY to $1.391 billion.
- **Strategic Acquisitions**: Shibo acquisition in China and Larsucosterol Phase III trial advance medical aesthetics and R&D pipelines.
- **Financial Strength**: $1 billion+ operating cash flow, $320 million debt reduction in Q4, and 2026 guidance for 3-4% growth.
- **Xifaxan Outlook**: 2026 peak year with 2027 EBITDA decline offset by Solta and International segment growth.
- **Bausch + Lomb Strategy**: Patient approach to separation, focusing on B+L value creation through pipeline execution.

**【Management Opening Remarks】**
- CEO Tom Appio highlighted 11 consecutive quarters of growth, driven by strong commercial execution and operational efficiency. Q4 revenue for Bausch Health (excluding Bausch + Lomb) rose 9% YoY to $1.391 billion, with adjusted EBITDA up 9% to $773 million. The company completed the acquisition of Shibo's aesthetics business in China, enhancing direct commercial presence.
- CFO Jean-Jacques Charhon emphasized financial discipline, with net debt reduced by $320 million in Q4 and a $1.7 billion debt exchange improving maturity profile. Full-year 2025 adjusted operating cash flow exceeded $1 billion.

**【CEO Commentary】**
- **Strategic Acquisitions**: Shibo acquisition positions Solta as a leader in China's aesthetics market, with plans to reclaim #1 geography status in 2026. Larsucosterol Phase III trial for alcohol-associated hepatitis (AH) began post-quarter end, reflecting R&D focus on unmet needs.
- **Segment Performance**: Salix delivered 9% revenue growth, driven by Xifaxan (11% YoY) and Thermage (19% YoY). Solta's South Korea market grew 40%, while International segment showed resilience in EMEA and LatAm despite Canada contraction.
- **2026 Outlook**: Guided for 3% revenue growth (midpoint $5.325 billion) and 4% EBITDA growth (midpoint $2.91 billion), with focus on AI-driven commercial efficiency and business development.

**【CFO Financial Commentary】**
- **Q4 Financials**: Consolidated revenue $2.796 billion (+9% YoY), adjusted EBITDA $1.52 billion (+13% YoY). Bausch Health (ex B+L) adjusted EBITDA margin expanded to 55.6%, up 120 bps YoY. Operating cash flow $515 million, with $362 million allocated to debt reduction.
- **2026 Guidance**: Revenue $5.25-5.4 billion, EBITDA $2.875-2.95 billion. Strong first-half phasing expected due to temporary 2025 benefits. Debt repayment flexibility enhanced by $9.6 billion refinancing.
- **Xifaxan Impact**: 2026 may be peak year due to Medicare rebate changes; 2027 EBITDA expected to decline ~$200 million, offset by growth in Solta and International segments.

**【Q&A Highlights】**
- **Business Development**: Focus on assets aligning with commercial excellence, including potential Solta and dermatology acquisitions. Larsucosterol Phase III powered for 50% mortality reduction in AH, with no approved therapies currently.
- **Solta Integration**: Shibo acquisition added $10-15 million EBITDA drag in Q4 due to purchase accounting, but China to drive mid-single-digit Solta growth in 2026.
- **Bausch + Lomb Separation**: No timeline for full separation; prioritizing B+L value creation through pipeline execution and margin expansion. Refinancing provides flexibility to monetize stake opportunistically.
- **Xifaxan Generics**: 2028 exclusivity maintained via patent litigation; 2027 EBITDA expected to average flat vs 2025, with 2026 growth offsetting 2027 decline.

Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript

- **Record Growth**: 10th straight quarter of revenue/EBITDA growth, with Q3 revenue +7% YoY and EBITDA +7% YoY (18% ex-R&D). 
- **Star Performers**: Xifaxan volume +9%, Cabtreo +186%, Solta +25% (South Korea +96%). 
- **Guidance Upped**: Full-year EBITDA midpoint +$50M to $2.725B, cash flow +$150M to $1.0B. 
- **Strategic Moves**: $7.9B debt refinancing, DURECT acquisition for hepatology pipeline. 
- **CMS Impact**: 30% of Xifaxan in Medicare Part D; final IRA pricing Nov 30, 2025. 
- **Debt Focus**: Target deleveraging via $600M+ annual cash flow and asset sales.

**【CEO Summary Section】**
- Bausch Health (excluding Bausch + Lomb) achieved 10 consecutive quarters of revenue and adjusted EBITDA growth, with Q3 2025 revenue up 7% YoY (5% organic) and adjusted EBITDA up 7% YoY (18% excluding a $81M R&D charge). 
- Key growth drivers: Solta (+25% reported, +24% organic), Salix (+12% reported, +11% organic), and products like Xifaxan (+16% revenue, +9% volume), Cabtreo (+186%), and Thermage (+300,000+ treatments globally). 
- Raised full-year guidance: Revenue $5.0-5.1B (midpoint +$25M), EBITDA $2.7-2.75B (midpoint +$50M), and cash flow $975-1.025B (midpoint +$150M). 
- Strategic priorities: Innovation (e.g., DURECT acquisition), value unlocking (e.g., $7.9B debt refinancing), and capital optimization. 

**【CFO Financial Commentary】**
- Consolidated Q3 revenue: $2.68B (+7% YoY), adjusted EBITDA: $986M (+8% YoY), and cash flow: $508M. 
- Bausch Health (excluding Bausch + Lomb): Adjusted EBITDA $773M (+7% YoY, +18% ex-R&D charge). 
- Salix: Xifaxan volume +9%, driven by AI customer insights and DTC campaigns (71,000 new patients Q3). 
- Solta: South Korea revenue +96% YoY, U.S. +double digits, Thermage Canada launch. 
- Diversified segment: Cabtreo +186%, Jublia +11%, offset by neurology headwinds. 
- CMS IRA impact: 30% of Xifaxan volume in Medicare Part D; final pricing disclosed Nov 30, 2025. 

**【Q&A Highlights】**
- **Xifaxan dynamics**: Q3 script growth (9% TRx, 14% new patients) outpaced revenue due to one-time gross-to-net benefit. CMS IRA impact expected in 2027. 
- **Pipeline updates**: RED-C Phase III readout Q1 2026; DURECT's larsucosterol targeting alcohol-associated hepatitis. 
- **Debt strategy**: Prioritize deleveraging via free cash flow ($600M+ annual) and asset sales (e.g., Bausch + Lomb stake). 
- **SG&A trends**: Q3 lower due to non-recurring accrual adjustments; expect Q1/Q2 2025 run rate for 2026 guidance. 
- **Generic risk**: Assume typical erosion curve for Xifaxan post-2028 patent expiry.

Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript

- **Strategic Acquisitions**: DURECT deal to expand hepatology pipeline, with potential for high-impact projects.
- **Operational Momentum**: 9+ quarter growth streak, driven by Xifaxan's 12%+ performance.
- **Balanced Capital Allocation**: Debt reduction to maintain flexibility while optimizing risk-adjusted opportunities.

**【CEO Summary Section】**
- **Strategic Acquisitions & Growth Initiatives**: Announced acquisition of DURECT Corporation to leverage hepatology expertise, with potential for pipeline expansion.
- **Operational Excellence**: 9 consecutive quarters of organic growth in Salix, driven by Xifaxan's 12% YoY growth and 8% new patient starts.
- **Market Expansion**: Solta Medical's Next Generation Fraxel launch in the U.S., signaling diversification beyond Asia-Pacific markets.

**【CFO Financial Commentary】**
- **Financial Strength**: Q2 2025 performance with $1.25B+ revenue and 10% EBITDA growth, supported by operational efficiency and cost management.
- **Capital Allocation**: $900M debt reduction to optimize capital structure, balancing risk-adjusted opportunities.

**【Q&A Highlights】**
- **Xifaxan IRA Negotiations**: Ongoing discussions to balance savings and growth opportunities, emphasizing health care cost savings.
- **Rifaximin SSD Trials**: Focus on unmet medical need projects, leveraging existing expertise.


Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: 6% YoY growth (excl. Bausch + Lomb) with 8 straight quarters of expansion, driven by Xifaxan (+8%) and Solta (+33%).
- **Debt Refinancing Success**: $7.9B refinancing extends maturity runway, reducing refinancing risk despite 100bps cost increase.
- **Litigation Win**: DC District Court ruling preserves Teva's first-filer status, safeguarding Xifaxan exclusivity.
- **Cash Flow Management**: Q1 operating cash flow $110M, with $1B+ liquidity to cover 2028 maturities.
- **Innovation Momentum**: RED-C Phase 3 data expected H2 2026; CABTREO script growth +89% YoY in U.S.


**【CEO Opening Remarks】**
- Q1 2025 revenue (excl. Bausch + Lomb) grew 6% YoY, with 8 consecutive quarters of top-line growth. Adjusted EBITDA increased 14% YoY to $576M.
- Completed $7.9B refinancing to extend debt maturities, reducing near-term refinancing risk.
- Secured favorable court ruling in Norwich litigation, maintaining Teva's first-filer status for rifaximin.
- Xifaxan grew 8% YoY, driven by 59,000 new patients and 33% organic growth in Solta's aesthetic devices.
- Maintaining full-year 2025 guidance: $4.95B-$5.10B revenue, $2.625B-$2.725B EBITDA.

**【CFO Financial Breakdown】**
- Q1 revenue (excl. Bausch + Lomb): $1.12B (+6% YoY). Salix segment grew 6% organically, Solta +33% organically (South Korea +136%, China +30%).
- Adjusted gross margin: 69.9% (-130bps YoY). Operating expenses rose $78M YoY, driven by R&D and SG&A investments.
- Adjusted operating cash flow: $110M (-4% YoY), impacted by higher interest payments post-refinancing.
- Bausch + Lomb segment revenue +5% YoY, benefiting from strong consumer demand in North America.

**【Q&A Key Takeaways】**
- **Tariffs & Supply Chain**: Solta's China business resilient despite tariffs; manufacturing remains in U.S. Xifaxan API sourced from Italy, finished goods manufactured in Canada.
- **Debt Management**: Post-refinancing, $5.6B maturities extended to 2028+. $1B+ cash on hand to cover remaining maturities.
- **Share Buybacks**: Stock undervalued at $5.25; evaluating buybacks alongside debt reduction, prioritizing capital structure optimization.
- **Litigation Update**: Norwich case resolved; no immediate impact on Xifaxan exclusivity. Focus on RED-C Phase 3 data (expected H2 2026) for cirrhotic patient expansion.
- **Innovation Pipeline**: CABTREO script growth +89% YoY; GMRx2 triple-combination hypertension therapy launching in Latin America Q2.


Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

- **Record 2024 Performance**: 7 straight quarters of top/bottom line growth, with $4.834B revenue and $2.553B EBITDA. 
- **Star Products**: Xifaxan (+16%), Solta (+34%), and International (+9% in Canada) drove growth. 
- **2025 Outlook**: 4% revenue growth ($4.95-5.1B), 5% EBITDA expansion, and $1B+ cash flow. 
- **Debt Reduction**: $1B net debt reduction in 2024; planning $700M facility with BLCO shares. 
- **Strategic Moves**: New Mexico cardiometabolic deals, AI adoption in sales, and RED-C Phase III trials. 
- **Risks**: Norwich litigation uncertainty, Medicare price talks, and potential tariffs. 


**【CEO Summary Section】**
- Bausch Health delivered 7 consecutive quarters of revenue and adjusted EBITDA growth, with Q4 2024 revenue up 4% (reported) and 7% (organic) for Bausch Health (excluding Bausch + Lomb). Key drivers included Xifaxan (16% growth) and Solta (34% growth). 
- 2024 full-year revenue: $4.834 billion (5% growth), adjusted EBITDA: $2.553 billion (8% growth), adjusted operating cash flow: $1.3 billion (85% YoY increase). 
- Strategic priorities: 
  1. Enhancing operational asset value through innovation (e.g., AI in Xifaxan sales process) 
  2. Unlocking Bausch + Lomb equity stake value 
  3. Optimizing capital structure (debt reduction, extended maturities) 
- 2025 guidance: Revenue $4.95-5.1 billion (4% growth), adjusted EBITDA $2.625-2.725 billion (5% growth), operating cash flow $975-1.025 billion. 

**【CFO Financial Commentary】**
- Q4 2024 financial highlights: 
  - Revenues: $2.559 billion (6% YoY growth) 
  - Adjusted EBITDA: $935 million (7% YoY growth) 
  - Adjusted operating cash flow: $601 million (38% YoY increase) 
- Full-year 2024 metrics: 
  - Adjusted gross margin: 71.9% (up 90bps YoY) 
  - Operating expenses: $3.812 billion (12% YoY growth) 
  - Debt reduction: $1 billion (net debt down $520 million in Q4 alone) 
- Capital structure updates: 
  - Secured $700 million credit facility 
  - Planning to pledge Bausch + Lomb shares for 2027+ maturity refinancing 
  - 2025 cash flow expected to support debt reduction without new funding needs. 

**【Q&A Key Highlights】**
1. **Norwich Litigation**: 
   - FDA denied Norwich's ANDA approval, citing Teva's first-filer status. Bausch Health supports FDA decision; no at-risk launch planned. 
2. **Xifaxan Medicare Negotiations**: 
   - 2027 IRA price talks ongoing; focus on demonstrating cost savings from HE indication. 
3. **Capital Markets Access**: 
   - Exploring BLCO share pledges for $700 million facility; no impact on BLCO separation timeline. 
4. **International Expansion**: 
   - New Mexico/Latin America cardiometabolic deals add $2+ billion market opportunity. 
5. **AI Adoption**: 
   - AI tools for Xifaxan sales process contributed to 2024 growth; exploring further AI applications. 
6. **Legal Settlements**: 
   - Granite Trust resolution expected soon; no material cash impact anticipated. 
7. **Tariff Impact**: 
   - Potential 25% tariffs on API imports could add <$50 million annual cost. 
8. **Pipeline Updates**: 
   - RED-C Phase III trials on track for 2026 readouts; amiselimod Crohn's study discontinued due to limited differentiation. 


Actual												0.8809	0.4435	1.2877	1.3095	0.9664	0.959	1.1251	1.2796	0.7532	0.5544	0.785	1.0468	0.5526	0.8253	1.0898	0.9894	0.6371	1.0781	1.1764	1.1266	0.5836	1.0631	1.163	1.0686
Forecast												0.8646	0.6567	1.0054	1.1294	0.9458	0.9611	1.0285	1.1086	1.0486	0.911	0.8155	0.9438	0.6497	0.7076	0.9265	1.0386	0.6884	0.8794	1.047	1.1272	0.805	0.9345	1.0618	1.213	0.6673
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.89%	-32.47%	+28.08%	+15.95%	+2.18%	-0.22%	+9.39%	+15.42%	-28.17%	-39.14%	-3.74%	+10.91%	-14.95%	+16.63%	+17.63%	-4.74%	-7.45%	+22.59%	+12.36%	-0.05%	-27.50%	+13.76%	+9.53%	-11.90%	0.00%

BHC

BHC fundamentals

BHC Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

BHC

BHC fundamentals

BHC Q1 2026 Earnings Preview

Earnings Call

BHC Earnings Call Summary for Q1/2026Upcoming5:00 PM on Apr 29, 2026

BHC Earnings Call Summary for Q4/20255:00 PM on Feb 18, 2026

BHC Earnings Call Summary for Q3/20255:00 PM on Oct 29, 2025

BHC Earnings Call Summary for Q2/20255:00 PM on Jul 30, 2025

BHC Earnings Call Summary for Q1/20255:00 PM on Apr 30, 2025

You can ask Aime